Jose Silva

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 11

Top Venues

Nature cancer

EMBO reports

Journal of cell science

This page only lists publications with an associated author ORCID identifier.

Publications

Jose Silva, Jiyang Yu, Kevin M Kalinsky
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor. Nature cancer (2023)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Rachel L Werner, Erin A Nekritz, Koon-Kiu Yan, Bensheng Ju, Bridget Shaner, John Easton, Jiyang Yu, Jose Silva
Single-cell analysis reveals the Comma-1D cell line as a unique model for mammary gland development and breast cancer. Journal of cell science 135 (10) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Tizita Z Zeleke, Qingfei Pan, Codruta Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S Trivedi, Melissa K Accordino, Katherine D Crew, Dawn L Hershman, Matthew Maurer, Simon Jones, Anthony High, Junmin Peng, Andrea Califano, Kevin M Kalinsky, Jiyang Yu, Jose Silva
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. Nature cancer 4 (2) (2022)
Erin A Nekritz, Ruth Rodriguez-Barrueco, Koon-Kiu Yan, Meredith Leigh Davis, Rachel L Werner, Laura Devis-Jauregui, Partha Mukhopadhyay, Jiyang Yu, David Llobet-Navàs, Jose Silva
miR-424/503 modulates Wnt/β-catenin signaling in the mammary epithelium by targeting LRP6. EMBO reports 22 (12) (2021)

Jose Silva.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jose Silva